CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 4 Option exercise Chief Financial Officer acquired 19,967 shares (option exercise)
- 8-K Event Executive or director change
- DEF 14A Proxy Proxy Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale President and CEO sold 4,781 shares at $15.70 ($75,062)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 28,357 shares at $16.36 ($463,793)
- 4 Option exercise Chief Financial Officer acquired 3,000 shares (option exercise)
- 4 Open-market sale President and CEO sold 9,562 shares at an average $17.22 ($164,658)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 4 Other disposition Director disposed of 750,000 shares (other)
- 4 Open-market sale 10% owner sold 1,650,000 shares at an average $17.39 ($28,700,395)
- 4 Open-market sale Director sold 0 shares
- 4 Open-market sale Chief Financial Officer sold 21,517 shares at an average $19.81 ($426,340)
- 4 Open-market sale President and CEO sold 14,343 shares at $19.60 ($281,123)
- EFFECT Other Notice of Effectiveness
- 8-K Event Material agreement · Regulation FD disclosure
Page 32 of 41 · 801 filings